Psychedelic Stocks

Why Psychedelics Yield Meaningful Experiences

Psychedelics have been subject to intense public and scientific scrutiny in recent years, thanks to claims of their medical efficacy. Countless studies have now found that psychedelics can induce profound mental changes in patients with hard-to-treat mental disorders such as post-traumatic stress disorder (PTSD) and major depressive disorder, putting psychedelics such as MDMA, LSD and psilocybin on track to becoming approved mental-health treatments.

However, long before scientists began running psychedelic clinical trials, regular and even casual psychedelics users knew one thing about this curious class of drugs: psychedelics could induce meaningful and often life-changing experiences in people who took them recreationally.

More than a century ago, Harvard philosopher William James inhaled nitrous oxide and noted that he felt a “tremendously exciting sense of metaphysical illumination.” The philosopher soon coined the term “noetic quality” of mystical experience to describe the powerful feelings of meaning he felt under the drug’s influence. This term described the feeling of confronting revelations of the highest magnitude and seeing the secret workings of your mind and the world laid bare.

However, due to the elusive quality of these encounters making them incredibly difficult to communicate, modern mainstream psychology has moved away from vague concepts such as noetic quality and adapted more objective and observable variables. More than a century after the Harvard philosopher came up with the term, a landmark paper by the late Roland Griffiths, founding director of the Johns Hopkins Center for Psychedelic and Consciousness Research, signaled the return of noetic insights to mainstream psychology, thanks to psychedelics.

According to Griffiths’ study, two-thirds of 30 volunteers who took psilocybin for two months rated the resulting psychedelic trips as among :five most meaningful experiences in their lives.” Subsequent studies that asked the same question found that up to 87% of participants rated their psychedelic experiences very highly, pointing to the exciting possibility that already existing chemicals may be able to help humans in their everlasting search for meaning.

Despite the recent rise in psychedelic-related studies, we still don’t fully understand how psychedelics address poor mental-health symptoms, let alone help people find meaning in their lives.  Given that psychedelic use is intimately tied with socialization and rituality, studies that map out brain regions while under psychedelic influence fail to deliver actionable results in the underlying mechanisms of various psychedelics.

Still, the general understanding is that psychedelics interact with serotonin receptors in the brain to influence functions such as sleep and mood. The brain’s salience network, which helps us determine what matters the most to us, may also play a role in how psychedelics yield meaningful experiences.

Hopefully, the research and development programs being undertaken by a host of psychedelic startups such as atai Life Sciences N.V. (NASDAQ: ATAI) will help to shed more light on how psychedelic substances trigger the therapeutic effects that initial research has shown that they can have.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 months ago